EGFR and non-small cell lung carcinoma: A trial investigating its utility as a monotherapy is currently recruiting and will include multiple cancer types, such as renal cell carcinoma (clear cell), NSCLC with EGFR mutations, and colorectal cancer (NCT04259450).